Article info
PDFPostScript
Letter
Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin’s lymphoma: the survival gain improves as more mature follow-up data become available
- Correspondence to Dr Andrea Messori, HTA Unit, Regione Toscana, Via Alderotti 26/N, 50135 Firenze, Italy; andrea.messori.it{at}gmail.com
Citation
Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin’s lymphoma: the survival gain improves as more mature follow-up data become available
Publication history
- First published November 30, 2020.
Online issue publication
October 18, 2023
Article Versions
- Previous version (22 April 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.